devinitorg/iati-policy-markers huggingface dataset:
Global Health Security Strengthening Project In 2021/22 DHSC’s Global Health Security Programme is providing £312,00 ODA funding toward a Global Health Security Strengthening Project delivered by Public Health England (PHE). A further £128,000 of non-ODA funding will be provided directly by PHE. The project has the primary purpose of providing the resource and technical expertise to increase PHE engagement on global health security at a global level, complementing and building on existing in-country work. It aims to share learning and knowledge from other PHE activity on global health security and seeks to expand and strengthen engagement with global organisations, initiatives and partnerships.
UK Vaccine Network - Clinical Vaccine Development Competition The Prime Minister established the UK Vaccine Network in June 2015 to ensure that the UK was at the forefront of the global fight against future disease outbreaks. The UK Vaccine Network has identified a range of human diseases with epidemic potential in low and middle income countries for which the development of Vaccine Products is a priority. The Department of Health and Social Care is collaborating with Innovate UK (an arms’ length body of the Department of Business, Energy and Industrial Strategy) in running this competition. Innovate UK has considerable expertise in running competitions of this nature. The competition was open to all organisations that were able to demonstrate that their product or work has a realistic route to market, whether in the short or long term, and is primarily for the benefit of low and middle income countries. Successful projects were awarded a research contract wholly funded by the Department of Health and Social Care and administered by Innovate UK. The Department of Health and Social Care made up to £35 million available to run the competition and fund the successful projects. This competition supports the clinical development of candidate vaccines and vaccine platform technologies which aim to tackle diseases of epidemic potential in low and middle income countries (LMICs). The UK Vaccine Network has identified 12 pathogens, which are of particular concern in LMICs, as a priority. The pathogens are: Chikungunya, Crimean-Congo Haemorrhagic Fever, Ebola, Hantavirus, Lassa, Marburg, Middle East Respiratory Syndrome, Nipah, Plague, Q Fever, Rift Valley Fever and Zika. The aim of this funding is to progress the development of vaccines for these priority diseases, ultimately to support an effective and rapid response during future outbreaks of disease. Populations of the low and middle income countries where outbreaks of the UK Vaccine Network 12 priority pathogens occur.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - UK-Argentina: tools to tackle AMR in the Environment This is a bilateral partnership with Argentina to support research to tackle antimicrobial resistance (AMR) in agriculture and the impact on the environment. Successful projects are a partnership of UK companies and research orgnisations, with Argentinian companies and research organisations. The competition and partnership will be delivered in the UK by the Biotechnology and Biological Sciences Research Council (BBSRC) in partnership with the Natural Environment Research Council (NERC), both part of UK Research and Innovation (UKRI), and delivered and matched-funded, on a resource basis, by the National Scientific and Technical Research Council (CONICET) in Argentina. The aim of this partnership is to generate new knowledge and provide a deeper evidence base that can help to reduce the impact of drivers of AMR in the environment from agricultural sources as they apply to Argentina and low- and middle- income countries (LMICs). This includes research towards the development of theroretical frameworks for surveillance and reporting on AMR and antibiotics, and research towards the development of strategies for manure, slurry and waste management. Projects are also required to produce outputs that translate research into policy, such as policy briefings or best practice position papers for LMICs. Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
Fleming Fund - Antimicrobial resistance (AMR) secondments Antimicrobial resistance (AMR) experts seconded to multilateral organisations through the Department of Health and Social Care's Fleming Fund. The Fleming Fund has seconded antimicrobial resistance (AMR) experts to work within the World Health Organisation (WHO), the Food and Agriculture Organisation (FAO) and the World Organisation for Animal Health (OIE). These secondees are to lead AMR activity that relates to the Fleming Fund and encourage collaborative working between multilaterals. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
Fleming Fund - Contribution to the International Reference Centre for Antimicrobial Resistance The Fleming Fund contribution to a UK draw-down service for technical assistance, training and quality assurance for low and middle income countries to support antimicrobial resistance (AMR) surveillance system building across all one-health sectors. The objectives of the reference centre are to: 1. Develop capacity of low- and middle-income countries (LMICs) for surveillance of AMR and antimicrobial use (AMU) through residential AMR training workshops, country visits to partners to offer training, provision of proficiency testing schemes; 2. Strengthen governance related to AMU and AMR by providing expert advice on new or emerging resistances that present a threat to animal or public health, providing expert advice on how to bench-mark capability and the authorisation of antibiotics and providing verification testing at our UK laboratories; 3. Promote good agricultural practices and prudent use of antimicrobials by providing advice and support for the adaptation and implementation of alternatives to antibiotics; and 4. Raise awareness of AMR by publishing and contributing to expert reports and peer-reviewed scientific manuscripts. Projects funded through the Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater
UK Vaccine Network - Vaccine Development Competition The Prime Minister established the UK Vaccine Network in June 2015 to ensure that the UK was at the forefront of the global fight against future disease outbreaks. The UK Vaccine Network has identified a range of human diseases with epidemic potential in low and middle income countries for which the development of Vaccine Products is a priority. The Department of Health and Social Care is collaborating with Innovate UK (an arms’ length body of the Department of Business, Energy and Industrial Strategy) in running this competition. Innovate UK has considerable expertise in running competitions of this nature. The competition was open to all organisations that were able to demonstrate that their product or work has a realistic route to market, whether in the short or long term, and is primarily for the benefit of low and middle income countries. Successful projects were awarded a research contract wholly funded by the Department of Health and Social Care and administered by Innovate UK. The Department of Health and Social Care made up to £11,323,617 available to run the competition and fund the successful projects. This competition supports projects seeking to develop vaccines, vaccine platform technologies and manufacturing technologies that will enable an effective, rapid response during future outbreaks of diseases of epidemic potential in low and middle income countries. The UK Vaccine Network has identified 12 pathogens, which are of particular concern in LMICs, as a priority. The pathogens are: Chikungunya, Crimean-Congo Haemorrhagic Fever, Dengue Virus, Ebola, Hantavirus, Lassa, Marburg, Middle East Respiratory Syndrome, Nipah, Plague, Q Fever, Rift Valley Fever and Zika. Following the initial stage of funding, successful projects were invited to apply for follow on funding. Four projects received this to undertake later stage, including early stage clinical, work. Populations of the countries where these diseases occur.
UK Vaccine Network - Preclinical Vaccine Development Competition The Prime Minister established the UK Vaccine Network in June 2015 to ensure that the UK was at the forefront of the global fight against future disease outbreaks. The UK Vaccine Network has identified a range of human diseases with epidemic potential in low and middle income countries for which the development of Vaccine Products is a priority. The Department of Health and Social Care is collaborating with Innovate UK (an arms’ length body of the Department of Business, Energy and Industrial Strategy) in running this competition. Innovate UK has considerable expertise in running competitions of this nature. The competition was open to all organisations that were able to demonstrate that their product or work has a realistic route to market, whether in the short or long term, and is primarily for the benefit of low and middle income countries. Successful projects were awarded a research contract wholly funded by the Department of Health and Social Care and administered by Innovate UK. The Department of Health and Social Care made up to £24,719,293 available to run the competition and fund the successful projects. This competition supports the preclinical development of candidate vaccines and vaccine platform technologies which aim to tackle diseases of epidemic potential in low and middle income countries. The UK Vaccine Network has identified 12 pathogens, which are of particular concern in LMICs, as a priority. The pathogens are: Chikungunya, Crimean-Congo Haemorrhagic Fever, Ebola, Hantavirus, Lassa, Marburg, Middle East Respiratory Syndrome, Nipah, Plague, Q Fever, Rift Valley Fever and Zika. Following the initial stage of funding, successful projects were invited to apply for follow on funding to support continued development of the vaccine products, including early stage clinical work. The aim of this funding is to progress the development of vaccines for these priority diseases, ultimately to support an effective and rapid response during future outbreaks of disease. Twenty two projects were supported through the first phase of the competition and seven were successful in the second stage of the competition. Populations of the low and middle income countries where outbreaks of the UK Vaccine Network 12 priority pathogens occur.
Fleming Fund - ODI Fellowships The economic fellowship scheme supports international secondments of a cadre of skilled health economists to low- and middle-income one-health Ministries, such as Health, Agriculture and Environment. The programme is designed to uplift and build the capacity of Fleming Fund partner countries in several core economic competencies that underpin the development of evidence-based policy relevant to addressing antimicrobial resistance (AMR). The project will aim to build capacity in 1. Economic analysis of relevant data (including AMR and antimicrobial use (AMU) surveillance data); 2. Economic appraisal of policy options, including cost/benefit analyses; 3. Research capacity in the review of regulations, incentives and opportunities that shape AMU; and 4. Gap analysis of public health data to provide a coherent demand side perspective on what data is required (in what format) to support economic analysis and policy development. Projects funded through the Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Developing a market shaping framework for AMR interventions in developing countries CHAI (Clinton Health Access Initiative) is a global health organisation committed to saving lives and reducing the burden of disease in low-and middle-income countries. It works with partners to strengthen the capabilities of governments and the private sector to create and sustain high-quality health systems that can succeed independently. Market Shaping with CHAI is a partnership between the UK government and the Clinton Health Access Initiative (CHAI) to support in-country landscaping (Kenya, Malawi, India, Laos, Vietnam) to collect data on the various dimensions of the AMR spectrum, with an aim to inform the identification of any large-scale interventions. The UK government has invested £645K over a 5-month period into CHAI. This is also supported by Cornell University in the United States working in advisory capacity. Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
WHO Framework Convention on Tobacco Control 2030 (FCTC 2030) Strengthening tobacco control in low and middle income countries. The Department of Health and Social Care has provided Official Development Assistance (ODA) funding for the FCTC 2030 project to promote implementation of the WHO Framework Convention on Tobacco Control (WHO FCTC) in low and middle income countries, in order to reduce global tobacco consumption and support the development of ODA recipient countries. The project will support low and middle income countries to strengthen tobacco control by: • implementing the requirements of Article 5 (general obligations) of the WHO FCTC, to improve tobacco control governance, • increasing tobacco tax, • implementing the two World Health Organisation Framework Convention on Tobacco Control (WHO FCTC) time-bound measures on (i) tobacco packaging and (ii) ending tobacco advertising), and • implementing other Articles of the WHO FCTC according to national priorities.
Fleming Fund - Vietnam Pilot Project Fleming Fund pilot project to build an antimicrobial resistance (AMR) reference laboratory and support an AMR surveillance network in Vietnam. The Vietnam pilot project aimed to: 1. Develop an AMR reference laboratory including setting up the required infrastructure and recruitment and training of a surveillance team and; 2. Develop a national AMR surveillance programme. As a result of this work, Vietnam has developed its first stage of laboratory infrastructure at the National Hospital of Tropical Diseases in Hanoi. Equipment has been installed, staff recruited and trained, and surveillance networks strengthened.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - New Antibiotic for Drug-Resistant Gonorrhoea with GARDP The Global Antibiotic Research & Development Partnership (GARDP) is a non-profit product development partnership. It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access of new or improved antibiotic treatments. UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support GARDP’s programme on sexually transmitted infections (STI), specifically focusing on the development of a new antibiotic for drug-resistant gonorrhoea. The aim of this project is to fund and support the development of new treatments that address the threat of drug-resistant gonorrhoea in low- and middle- income countries (LMICs). Objectives of the funded activity are to: - develop a new affordable treatment for gonorrhoea, that works on multi-drug resistant cases (trials completed and registration started by 2022) - support the integration of the new treatments into the current Sexually Transmitted Infection management framework by investigating possible antibiotic combinations by 2023; and - support the development of a stewardship and access strategy for LMICs for the new antibiotic treatment. Projects funded through GAMRIF will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
Fleming Fund - GRAM Global Burden of Disease Project Grant to University of Oxford/Institute of Health Metrics and Evaluation to collect, synthesise and visualise data on the burden of disease associated with anitmicrobial resistance (AMR), quantify the problem and promote policy attention and resource allocation to tackle the issue. To collect data on the burden of disease associated with antimicrobial resistance (AMR) in low- and middle-income countries (LMICs), synthesise this data, and ensure that AMR is included within the Global Burden of Disease study. Projects funded through Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - New Antibiotic for Drug-Resistant Gonorrhoea with GARDP The Global Antibiotic Research & Development Partnership (GARDP) is a non-profit product development partnership, hosted by the Drugs for Neglected Diseases Initiative (DNDi) and started in association with the World Health Organisation (WHO). It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access of new or improved antibiotic treatments. UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support GARDP’s programme on sexually transmitted infections (STI), specifically focusing on the development of a new antibiotic for drug-resistant gonorrhoea. The aim of this project is to fund and support the development of new treatments that address the threat of drug-resistant gonorrhoea in low- and middle- income countries (LMICs). Objectives of the funded activity are to: - develop a new affordable treatment for gonorrhoea, that works on multi-drug resistant cases (trials completed and registration started by 2022) - support the integration of the new treatments into the current Sexually Transmitted Infection management framework by investigating possible antibiotic combinations by 2023 Projects funded through GAMRIF will primarily benefit people in low- and middle-income countries, where the burden of drug-resistant infection is greater.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Vaccine Innovation with BactiVac Vaccine Innovation with BactiVac is a partnership between the UK government and the Bacterial Vaccinology Network (BactiVac) to support the development of vaccines for AMR in humans and animals. The UK government has invested up to £1 million over one year into BactiVac, which is one of 5 networks that are supported by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research & Development. This is co-funded by the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC). The primary aim of this investment is to support new, diverse research projects to gain preliminary data and encourage establishment of new research partnerships, and allow these collaborations to build a track record, which will allow them to attain further funding. It is expected that some of these projects will fail, yet the dissemination of both positive and negative research outcomes is valuable and expected. Funded projects will undertake early stage research and development with catalyst pump-priming funding around the world to help drive the development and uptake of vaccines for antimicrobial resistance (AMR) for the benefit of people in low- and middle-income countries (LMICs). Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - GARDP Core Funding The Global Antibiotic Research & Development Partnership (GARDP) is a non-profit product development partnership. It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access of new or improved antibiotic treatments. UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support GARDP’s core activities. DHSC will provide unearmarked, core funding to GARDP to support the development and delivery of new treatments for drug-resistant infections that pose the greatest threat to health, with GARDP having a primary focus to enable distribution of treatments to people in low- and middle-income countries and with antimicrobial resistance (AMR) recognised by the UN General Assembly as critical to achieving the Sustainable Development Goals (SDGs).
Fleming Fund - Commonwealth Partnerships for Antimicrobial Stewardship Scheme A partnership programme to improve antimicrobial stewardship across Zambia, Tanzania, Ghana, Uganda, Sierra Leone, Kenya, Malawi and Nigeria. The partnerships leverage the expertise of UK health institutions and technical experts to strengthen the capacity of the national health workforce and institutions to address predefined antimicrobial resistance (AMR) challenges. The project aims to 1. Develop partnerships between NHS Trusts (hospitals) and clinics/hospitals in low- and middle-income commonwealth countries. 2. Share UK expertise abroad as well as bring skills and knowledge back to NHS Trusts. 3. Create focused partnerships on the theme of AMR, that includes activity on; Antimicrobial stewardship, including surveillance (AMS); Infection prevention control and Antimicrobial pharmacy expertise and capacity; and 4. More generally improve the knowledge, skills and empowerment of healthcare professionals and pharmacists in partner institutions. Improving the healthcare workforce to ultimately contribute to a strengthened health system. Projects funded through the Fleming Fund will benefit people in low- and middle-income countries, where the burden of drug resistant infection is greater